TET2 and acute myeloid leukemia: To directly link these enhancers to their target genes, we analyzed 3D genome interactions generated using in situ HiC from both normal CD34+ cells [32] and three primary AML samples [31] (all were wild type for DNMT3A, IDH1, IDH2, and TET2).